Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.41 |
| ▸ | CTSL | P07711 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | UGCG | Q16739 | 6/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6895691 | 1.00 | HSD17B10 (0.42) | HSD17B10CHRM1CTSLALDH1A1KDM4E | |
| SCHEMBL6896682 | 0.93 | HSD17B10 (0.42) | HSD17B10CHRM1CTSLALDH1A1KDM4E | |
| SCHEMBL27538309 | 0.93 | HSD17B10 (0.47) | HSD17B10CHRM1CTSLALDH1A1UGCG | |
| SCHEMBL6895429 | 0.93 | HSD17B10 (0.47) | HSD17B10CHRM1CTSLALDH1A1UGCG | |
| SCHEMBL6895008 | 0.93 | HSD17B10 (0.42) | HSD17B10CHRM1CTSLALDH1A1KDM4E | |
| SCHEMBL6891051 | 0.93 | HSD17B10 (0.47) | HSD17B10CHRM1CTSLALDH1A1UGCG | |
| SCHEMBL6896860 | 0.92 | HSD17B10 (0.41) | HSD17B10CHRM1CTSLALDH1A1KDM4E | |
| SCHEMBL27538227 | 0.92 | HSD17B10 (0.41) | HSD17B10CHRM1CTSLALDH1A1KDM4E | |
| SCHEMBL27538348 | 0.91 | HSD17B10 (0.43) | HSD17B10CHRM1CTSLALDH1A1KDM4E | |
| SCHEMBL6897650 | 0.91 | HSD17B10 (0.40) | HSD17B10CHRM1CTSLALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6730784-B2 | AS THERAPEUTIC AGENTS FOR AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2004-05-04 | — | — | US | disclosed |
| US-20020198376-A1 | Novel urea derivatives | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-12-26 | — | — | US | disclosed |
| US-6492370-B1 | Urea derivatives and pharmaceutical compositions thereof | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-12-10 | — | — | US | disclosed |
| EP-1072591-A1 | NOVEL UREA DERIVATIVES | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2001-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198376-A1 | Novel urea derivatives | TNF, CTH, CFH | HSD17B10 1909/4885CHRM1 340/4885CTSL 869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.